Interactive Question 9

May 28, 2013

Question:

Which of the following statements about the risks of bleeding with antiplatelet therapy is true?

Answers

Answer:

risk of bleeding is similar with 81mg and 325mg of aspirin

Correct Answer?

Explanation:

Incorrect. Several trials have shown that higher doses of aspirin increase bleeding risk without improving efficacy. Aspirin doses of about 81 daily appear to optimize the benefit-risk tradeoff in most patients.

Answers

Answer:

as compared to clopidogrel (Plavix), the newer antiplatelet agents – prasugrel (Effient) and ticagrelor (Brilinta) – reduce the rate of cardiovascular events similarly without increasing bleeding risk among patients with acute coronary syndromes

Correct Answer?

Explanation:

Incorrect. Prasugrel and ticagrelor are more potent than clopidogrel, which leads to a greater reduction in the rate of ischemic events, but also a higher risk of bleeding.

Answers

Answer:

adding a newer antiplatelet agent (clopidogrel [Plavix], prasugrel [Effient], ticagrelor [Brilinta]) to aspirin does not increase the risk of bleeding compared to aspirin alone

Correct Answer?

Explanation:

Incorrect. As compared to aspirin alone in the treatment of acute coronary syndromes, dual antiplatelet therapy can prevent more vascular events, but increases the risk of major bleeding.

Answers

Answer:

all antiplatelet agents increase the risk of intracranial bleeding

Correct Answer?

Explanation:

Correct. All antiplatelet agents increase the risk of gastrointestinal and intracranial bleeding, including low-dose aspirin.

Format:

Radio buttons (single select)

(781) 893-4610 | General Support: (617) 841-2925 or support@mms.org